Dear Editor,
Patients with undifferentiated (anaplastic) thyroid carcinoma (ATC) are refractory to surgical treatment, chemotherapy, and/or radiotherapy, and have a dismal prognosis (Smallridge et al. 2012) . Distant metastasis occurs at various sites and is poorly sensitive to chemotherapy or radiotherapy. As a result of aggressive tumor behavior and ineffective therapeutic efficacy, patients do poorly (Besic & Gazic 2013) . Positron emission tomography (PET)/computed tomography (CT) is the primary imaging modality for ATC at initial staging and has utility in the early evaluation of treatment response and follow-up (Poisson et al. 2010) . Distant metastases, extensive local infiltration, and regional lymph node metastases have been found at autopsy in 91, 76, and 51% of cases respectively. Regional and distant metastases are shown to be present in 51% of cases, with 40% of cases showing distant metastases alone. The most common site of metastasis is the lung (78%), followed by intrathoracic lymph nodes (58%), neck lymph nodes (51%), pleura (29%), adrenal glands (24%), liver (20%), brain (18%), and heart (18%) (Besic & Gazic 2013) . Lung metastases are present in 34 of 38 (89%) cases, with distant metastases found at autopsy, and are known to be present in 27 of these patients while alive. In most patients, lung metastases are detected by chest X-ray (Besic & Gazic 2013) . Several genetic alterations are reported in the pathogenesis of ATC, including RAS, BRAF, TP53, CTNNB1 (b-catenin), VEGFR1, VEGFR2, KIT, MET, PIK3C, FOXA1, etc. (Liu et al. 2008 , Nucera et al. 2009 , Smallridge et al. 2012 , Antonello & Nucera 2013 . The BRAF V600E mutation is the most prevalent genetic alteration in PTC (frequency of about 60%) and may be associated with tumor progression of PTC to ATC (frequency: about 15-44%) (Ricarte-Filho et al. 2009 , Cancer Genome Atlas Research Network 2014 , Shi et al. 2015 . Importantly, although pre-clinical (Nehs et al. 2010 (Nehs et al. , 2012 and clinical (Rosove et al. 2013) Zheng et al. 2014) in six ATCs (high grade malignant pleomorphic cell neoplasms). We found for the first time that one out of six (16.6%) ATC showed overall frequency of the co-occurrence of PTEN p.Cys105LeufsTer2 (c.309_310insT) and TP53 p.Pro153A-lafsTer28 (c.455insC) frameshift insertions (identified from 39 genes analyzed, including analysis of 1799TOA BRAF V600E mutation and translocations of RET, ALK, and ROS1) (Table 1 and Fig. 1 ). These insertions were present in both primary ATC and in metastatic brain foci which showed increased angiogenesis. Targeted NGS is based on innovative high-throughput screening which is fundamental to identify genomic alterations potentially causative of thyroid cancer progression and drug-resistance. The resulting genomic variants were filtered (Supplementary Materials and Methods, see section on supplementary data given at the end of this article and Tumor sequencing was performed on formalin-fixed paraffin-embedded (FFPE) tissues using anchored multiplex PCR (AMP), a multiplex PCR assay developed to detect single nucleotide variants (SNVs) and insertion/deletion (indel) in genomic DNA, using targeted next-generation sequencing (NGS). The genomic DNA was sheared with the Covaris M220 instrument, followed by end repair, adenylation, and ligation with an adapter. A sequencing library targeting hotspots and exons in 39 genes (including analysis of 1799TOA BRAF V600E mutation and translocations of RET, ALK, and ROS1)
was generated using two hemi-nested PCRs. Illumina MiSeq 2!151 bp-end sequencing results were aligned to the hg19 human genome reference using BWA-MEM. MuTect and a laboratorydeveloped insertion/deletion analysis algorithm were used for SNV and indel variant detection respectively. Oncotator was used for mutation annotation. Minimal thresholds of 100! coverage and 5%
allelic fraction were applied. The filters include a panel of normal DNAs. The resulting variants were filtered against SNP databases (including dbSNP 1000 Genomes Project) and annotated using the Bioconductor Variant Annotation package. Overall coverage was calculated using a 21-bp window for hotspot point mutation targets (G10 bp) and 5-bp intronic flanks for whole exon targets. a 1.6 cm enhancing mass in the posterior left parietal lobe of the brain with surrounding edema but no midline shift. Following admission at a local hospital, she experienced two seizures with subsequent craniotomy and resection of a left occipital mass. Histologic review confirmed a metastatic high-grade carcinoma with multifocal necrosis (Fig. 1) . Immunohistochemistry demonstrates tumor cells to express CK7, AE1/3, TTF-1 (diffusely positive), and Fig. 1 ), Napsin-A (Supplementary Fig. 1 ), CK20, CD10, HMB45, SOX10, ER, mammaglobin, chromogranin, TP53 ( Supplementary  Fig. 1 ), and GFAP. The ki67 tumor proliferative index is up to 80%. Immunohistochemical staining with an antibody directed against CD31 demonstrated intra-and peritumoral blood vessels (increased angiogenesis; Supplementary Fig. 1) , and absence of D2-40 staining highlighted a dearth of lymphatic spaces. Positivity for keratins, TTF-1 and PAX8 with negative napsin-A ( Supplementary Fig. 1 (Fig. 1 ) arises in association with a poorly differentiated thyroid carcinoma with clear cell and oncocytic features, widely invasive, with extensive vascular invasion, locally intrathyroidal, with negative surgical margins. Ki67 proliferative index was up to 50%. TTF-1 nuclear expression was focal, rare and weak (Fig. 1) ; whereas, PAX8 nuclear expression was multi-focally positive and keratin seven marked rare ATC cells. The ATC was negative for thyroglobulin (retained in surrounding normal thyroid as control) (Fig. 1) , TP53 ( Fig. 1) , and b-catenin (normal membranous staining). PTEN expression was lost in tumor cells (retained in surrounding normal thyroid as control) (Fig. 1) . TTF-1 is often lost in ATC or may be focal. PAX8, another thyroid transcription factor, is often more consistently retained in ATC, even though often reduced in overall expression. Therefore, the two immunostains are usually run in tandem, as one stain may show better expression than the other. These tumors often display variable tumor morphology, with a combination of a better differentiated tumor and an undifferentiated tumor. It is likely that the variable expression of these early differentiation-inducing transcription factors contributes to the diverse morphologies of ATC, with distinct heterogeneity even with a single tumor. Additionally, these changes might be noted by varying expression levels of any individual antigen in primary vs metastatic tumor, depending upon which clonal population of the tumor has spread. Importantly, our genomic analysis revealed PTEN (c.309_310insT) and TP53 (c.455insC) frameshift insertions (Fig. 2) as genetic aberrations in the primary ATC specimen. The patient died of disease 10.5 months following her initial brain surgery and subsequent thyroid lobectomy with no evidence of residual disease in the thyroid bed (March 2015). However, she did have residual brain disease and was subsequently involved in a clinical trial. The clinical presentation is atypical in many ways, primarily as she presented with distant symptoms rather than primary symptoms. The fact that her primary tumor was still resectable at the time of diagnosis of brain metastasis is extraordinary and very atypical for this diagnosis. In summary, ATC is a biologically aggressive malignancy with a complex tumor microenvironment (Nucera et al. 2011 , Duquette et al. 2013 prone to rapid local growth and distance metastasis. Here, we identify, for the first time, concomitant frameshift insertions in PTEN and TP53 associated with brain metastasis. Most patients with ATC die from local symptoms, including loss of airway and hemorrhage. The reason we present this case as unique is specifically because it is such an unusual presentation with brain metastasis rather than local symptoms. And, even more remarkably, the patient had a resectable thyroid tumor. This indicates that the tumor biology in this case allowed for early metastasis to a site in the brain that facilitated early clinical attention rather than to a place that would allow for more insidious advancement of the tumor prior to clinical presentation. The genetic alterations seen in this tumor are in genes with known association with aggressive thyroid cancers, PTEN in differentiating thyroid cancers, albeit rare. In human carcinomas, monoallelic mutation of PTEN without loss or mutation of the second allele is prevalent at presentation, whereas complete loss is observed at low frequencies with the exception of advanced carcinomas (Salmena et al. 2008) . Similarly, TP53 is more often mutated in ATC (Kunstman et al. 2015) . How this combination of PTEN and TP53 insertions assert this tumor's behavior biologically is unclear.
PAX8 (diffusely positive). Tumor cells are negative for PTEN (lost) (Supplementary
Although ATC is known to be biologically aggressive with a complex tumor microenvironment, this particular clinical presentation and concomitant insertions may provide new insights for ATC treatment; specifically, because it is such an unusual manifestation with symptoms arising from the brain metastasis rather than its usual presentation with locally aggressive behavior. ATC harboring BRAF V600E present targeted adjuvant options; however, genetic alterations in PTEN and TP53 genes may represent a therapeutic challenge in patients with ATC harboring those aberrations, warranting the need for pre-clinical models to better elucidate the biological cooperation between PTEN and TP53 insertions and their underlying molecular mechanisms in ATC.
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